



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sara S. Bacus et al.

Docket No.: 6155-US-NP
(former 02-434-A)

Serial No: 10/600,129

Group Art Unit: 1643

Filed: June 19, 2003

Examiner: Anne L. Holleran

For: Method for Predicting Response to Epidermal Growth Factor Receptor-Directed Therapy

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. 3.73(b)

Abgenix, Inc. (hereinafter "Abgenix"), a corporation of the State of Delaware, and Immunex Corporation (hereinafter "Immunex"), a corporation of the State of Washington, are the assignees of the entire right, title, and interest in the above-identified U.S. patent application. Documentary evidence of a chain of title from the original owner(s) to Abgenix and Immunex are demonstrated by:

☐ the enclosed copy of an Assignment, the original of which is being filed for recordation by the United States Patent and Trademark Office.

OR

☒ the assignments recorded in the United States Patent and Trademark Office at:
Reel 015071 Frame 0836 and Reel 015094 Frame 0990.

The undersigned, whose titles are supplied below, is empowered to sign this statement on behalf of Abgenix and Immunex.

**REVOCATION OF PREVIOUS POWER OF ATTORNEY AND NEW POWER OF
ATTORNEY BY ASSIGNEE**

Amgen hereby revokes all previous powers of attorney given in the above-identified application and hereby appoints the registered practitioners at Customer Number **21069** to prosecute this application, to make and to transact all business in the Patent and Trademark Office connected therewith.

REQUEST FOR CHANGE OF CORRESPONDENCE ADDRESS

Please send all future correspondence and direct telephone calls to Customer Number **21069**.

Date: April 13, 2009

ABGENIX, INC.

IMMUNEX CORPORATION

By Stuart L. Watt
Stuart L. Watt

By Stuart L. Watt
Stuart L. Watt

Title: Vice President, Law

Title: Vice President, Law & Intellectual Property